Prinivil/Sandbox 1: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
== Function == | == Function == | ||
[[Image:LPR_mechanism.png|thumb|left|310×228px|link=http://proteopedia.org/wiki/images/a/af/LPR_mechanism.png|Figure 1]] <scene name='74/745974/Bradykinin/1'>Bradykinin</scene> is a common vasodilator that, when bound to ACE, will allow ACE the cleave angiotensin I to angiotensin II, but when bound to lisinopril, bradykinin levels rise in the blood stream causing a decrease in blood pressure and increased vasodilation. As seen in Figure 1, bradykinin will bind to the ACE, which allows for the conversion of angiotensin I to angiotensin II by the ACE/bradykinin complex. By blocking the active site of ACE, an inactive angiotensin 1 cannot be cleaved, which would block the cascade of events triggered by angiotensin 2 binding to type 1 AT2 receptor to create vasoconstriction. | [[Image:LPR_mechanism.png|thumb|left|310×228px|link=http://proteopedia.org/wiki/images/a/af/LPR_mechanism.png|Figure 1]] <scene name='74/745974/Bradykinin/1'>Bradykinin</scene> is a common vasodilator that, when bound to ACE, will allow ACE the cleave angiotensin I to angiotensin II, but when bound to lisinopril through competitive inhibition, bradykinin levels rise in the blood stream causing a decrease in blood pressure and increased vasodilation. As seen in Figure 1, bradykinin will bind to the ACE, which allows for the conversion of angiotensin I to angiotensin II by the ACE/bradykinin complex. By blocking the active site of ACE, an inactive angiotensin 1 cannot be cleaved, which would block the cascade of events triggered by angiotensin 2 binding to type 1 AT2 receptor to create vasoconstriction. | ||
== Structure and Mechanism == | |||
[[Image:Prinivil_Bradykinin_binding_sites.png|thumb|right|Figure 2. Lisinopril binding locations]]Lisinopril (prinivil) acts upon the membrane protein by forming tight and nonspecific contacts with the conserved residues in the <scene name='74/745974/Lisinopril_s2_interaction/1'>S2'</scene>, <scene name='74/745974/Lisinopril_s1_interaction/1'>S1'</scene>, and <scene name='74/745974/Lisinopril_s1_1_interaction/1'>S1</scene> positions of the <scene name='74/745974/Lisinopril_ace_complex/2'>ACE</scene>, which is viewed by using JSmol<ref>DOI 10.1002/ijch.201300024</ref> and Jmol.<ref>PMID:21638687</ref> The S1’ subsite contains Glu162 residue that interacts strongly with the lysine residue of lisinopril, the S1 subsite is surrounded with hydrophobic residues Phe512 and Val518, and the S2’ subsite contains Lys511 and Tyr520 to form strong hydrogen bonds with the C-terminus proline of lisinopril.<ref>DOI 10.1021/ci200083f</ref> The ACE Active site has a NH3+ group which binds to the COOH terminus of the drug. NH of the enzyme binds to the middle C=O group of the drug. The benzene ring of the drug fits into a hydrophobic pocket(S1) of the enzyme. The 5-membered nitrogenous ring of the drug fits to the S2’ pocket. The lysine segment fits into the S1’ pocket, as seen in Figure 2.<ref>Brew, K. Structure of human ACE gives new insights into inhibitor binding and design. TRENDS in Pharm. Sci. 2003 Aug; 24: 8. doi: 10.1016/S0165-6147(03)00199-8</ref> All other ACE inhibitors, such as Captopril, Fentiapril, Pivalopril, etc all have the same general substituents of a phenyl in the S1, lysine in the S1', and proline in the S2' pocket as well as a carboxyl group that binds with a Zn<sup>2+</sup> ion. | |||
== | |||
ACE Active site has a NH3+ group which binds to the COOH terminus of the drug. NH of the enzyme binds to the middle C=O group of the drug. The benzene ring of the drug fits into a hydrophobic pocket(S1) of the enzyme. The 5-membered nitrogenous ring of the drug fits to the S2’ pocket. The lysine segment fits into the S1’ pocket. | |||
- all | |||